Previous 10 | Next 10 |
2024-02-15 03:09:03 ET Summary Celestica's Q4 results were better than expected, but the focus should be on investor expectations rather than high-growth stocks. The Q1 2024 outlook for CLS is surprisingly strong, indicating a potential growth of 60% in EPS. The Company's valu...
2024-02-13 05:00:00 ET Summary The Tech Sector, XLK, dominated market performance in 2023, with seven of the biggest names capping off a banner year. SA Quant’s Top 10 Tech Stocks for 2023 were up 43.6%, outperforming the S&P 500 by almost 20%, including SMCI +255%, ACL...
Celestica Inc. (NYSE: CLS) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.58% on the day to $22.25. Celestica Inc. provides hardware platform and supply chain solutions in North America, Europe, and Asia. It operates through two segments, Advanced Technology S...
2024-02-02 02:58:15 ET Summary Celestica posts strong Q4 2023 financial results, beating revenue and earnings estimates. Connectivity & Cloud Solutions segment drives revenue growth and margin improvement. Promising outlook for FY 2024, with 14% YoY revenue growth expected...
2024-01-31 12:31:47 ET Summary Celestica and Sanmina Corporation both traded higher after posting quarterly results, but the response was different on a fundamental level. Sanmina's Q1 results were weak, but the stock rose unexpectedly due to short covering and an optimistic outlo...
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, is pleased to announce the appointment of Kulvinder (Kelly) Ahuja to its Board of Directors effective Ja...
2024-01-30 11:46:05 ET Celestica Inc. (CLS) Q4 2023 Earnings Conference Call January 30, 2024 08:00 AM ET Company Participants Craig Oberg - VP, IR & Corporate Development Rob Mionis - President & CEO Mandeep Chawla - CFO Conference Call Participant...
2024-01-30 08:39:01 ET Iterum Therapeutics ( ITRM ) +61% Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections. Kura Oncology ( KURA ) +16% Reports Positive Preliminary Ziftomen...
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (“ Celestica ” or the “ Corporation ”) (NYSE, TSX: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world’s most innovative companies, today announced ...
2024-01-30 02:51:31 ET More on Celestica Celestica: Why It Remains A Long-Term Strong Buy Why Celestica Stock Is A Buy Into Q4 Earnings Why Celestica Remains Among The Top Rated Stocks Heading Into 2024 Celestica announces TSX acceptance of normal course issu...
News, Short Squeeze, Breakout and More Instantly...
(All amounts in U.S. dollars. Per share information based on diluted shares outstanding unless otherwise noted.) TORONTO, July 24, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the worl...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...